Further, integrin αvβ3-positive NSCLC cells unveiled significant EGFR inhibitor resistance, leading to activating Galectin-3/KRAS/RalB/TBK1/NF-κB signaling pathway. Here, NFKB1 is linked to non-small cell lung carcinoma.